NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Income Statement
Europe - Euronext Oslo - OSL:NYKD - NO0010714785 - Common Stock
2.491 NOK
-0.06 (-2.39%)
| TTM (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.77M | 8.68M | 12.90M | 7.17M | 33.96M | |||
| Operating Expenses | 33.50M | 55.80M | 69.28M | 57.83M | 41.69M | |||
| Research and Development | N/A | N/A | 29.36M | 26.77M | 16.30M | |||
| Selling, General, and Administrative Expenses | 17.96M | 32.00M | 28.00M | 18.80M | 17.51M | |||
| Operating Income | -26.49M | -46.80M | -56.28M | -50.66M | -7.72M | |||
| Interest Income/Expense | N/A | 2.82M | 14.00M | 2.31M | -369.00K | |||
| Other Income/Expense | N/A | -818.00K | 0.00 | -137.00K | 27.00K | |||
| Non Recurring Items | N/A | -1.20M | -1.72M | -2.49M | -3.05M | |||
| Income Before Taxes | -16.65M | -46.00M | -44.00M | -50.98M | -11.12M | |||
| Income Tax | -5.64M | -6.69M | -8.93M | -8.24M | -1.70M | |||
| Net Income | -11.00M | -39.00M | -35.00M | -42.74M | -9.41M | |||
| EBITDA | -24.40M | -44.55M | -54.16M | -48.85M | -6.99M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.03 | -0.12 | -0.12 | -0.15 | -0.03 | |||
| Non GAAP EPS | N/A | -0.12 | -1.26 | N/A | N/A | |||
| Statistics | ||||||||
| Profit Margin | -162.43% | -449.36% | -271.28% | -596.30% | -27.72% | |||
| Operating Profit Margin | -391.17% | -539.23% | -436.21% | -706.81% | -22.75% | |||
All data in USD (non-GAAP EPS in NOK )